Molecular Templates (NASDAQ:MTEM) IND application for MT-5111, an engineered toxin body targeting HER2, has been accepted by the FDA. MT-5111’s single chain variable fragment and Shiga-like toxin-A subunit respectively...
Television station, CFJC, of Kamloops, British Columbia, Canada has produced a segment about the first patient in the region to receive Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphineas a new...
Canopy Growth (TSX:WEED; NYSE:CGC) entered a complex arrangement to acquire Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) when cannabis production and sale becomes federally legal in the U.S.
Canopy Growth (TSX:WEED; NYSE:CGC) completed an all-cash acquisition of Spain-based licensed cannabis producer, Cáñamo y Fibras Naturales, (Cafina). The acquisition lays the foundation for Canopy to expand its European...
Profound Medical (TSX:PRN; OTCQX:PRFMF) announced the first prostate cancer treatment using a first-of-its-kind TULSA-PRO installation in Trier, Germany. The installation combines Profound’s TULSA-PRO system with...
Albireo Pharma (NASDAQ:ALBO) presented positive Phase 2 data for its drug candidate, A4250, at The International Liver Congress 2019. A4250 is being developed to treat rare pediatric cholestatic liver diseases, where...
MediciNova (NASDAQ:MNOV) received FDA approval to conduct a Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis (ALS) patients. MN-166, or ibudilast, suppresses pro-inflammatory cytokines, promotes...
TG Therapeutics (NASDAQ:TGTX) received the FDA’s orphan drug designation for its phosphoinositide-3-kinase delta inhibitor, umbralisib, for the treatment of patients with marginal zone lymphoma (MZL). MZL is a slow...
Arrowhead Pharma (NASDAQ:ARWR) received FDA clearance to proceed with its adaptive Phase 2/3 trial evaluating ARO-AAT in patients with alpha-1 antitrypsin (AAT) deficiency-associated liver disease. AAT deficiency is a...
Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for opioid use disorder is now being used in patients across Canada. Approved by Health Canada in April 2018, Probuphine is the only subdermal implant designed to...
Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...
OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity. OPK-88003 is a dual GLP-1/glucagon...
KemPharm (NASDAQ:KMPH) met with the FDA to discuss the NDA for KP415, its attention deficit hyperactivity disorder (ADHD) drug candidate. KP415 consists KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated...
GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone. GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor...
Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV). The study enrolled 33...
TRACON Pharmaceuticals (NASDAQ:TCON) terminated for futility its Phase 3 TAPPAS trial, evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, based on a recommendation of...
Hancock Jaffe (NASDAQ:HJLI) has implanted VenoValves in four patients with severe, chronic venous insufficiency (CVI) as part of its first-in-human study of the device. CVI occurs when the valves in the veins of the leg...
Otonomy (NASDAQ:OTIC) initiated a Phase 1/2 trial of OTO-313, a novel formulation of gacyclidine, for the treatment of tinnitus. Patients with tinnitus experience noise or ringing in their ears. Otonomy notes that some...
ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...
Q BioMed (OTCQB:QBIO) has discovered two novel biomarkers for pediatric nonverbal autism (PNA) in a subset of children with autism spectrum disorder (ASD). Children with PNA never develop the ability to speak, or begin...
Concert Pharmaceuticals (NASDAQ:CNCE) initiated a multiple ascending dose (MAD) study to evaluate its adjunctive schizophrenia therapeutic candidate, CTP-692, in healthy volunteers. CTP-692 is a deuterium-modified...
Avinger’s (NASDAQ:AVGR) Pantheris SV (small vessel) image-guided atherectomy system, indicated for the diagnosis and treatment peripheral artery disease (PAD), has received 510(k) clearance from the FDA. Atherectomy is...